---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001831"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:43:24.982989+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025

## Summary
- Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.
- Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.
- First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.
- Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.
- Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025.

## SEC filing metadata
- accession: 0001641172-25-001831
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/0001641172-25-001831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001831
- JSON: https://secwatch.observer/filing/0001641172-25-001831.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.